Industry

Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA” or the “Agency”) has informed the Company that the Agency is planning to reconvene the Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) to discuss the New Drug Application (NDA) for AMX0035 (sodium … [Read more…]

With Its Acquisition of California-Based Bartel Associates, Foster & Foster Continues to Expand Its National Footprint as a Premier Actuarial Firm

Deal Will Extend Foster & Foster’s Reach in the West Coast Actuarial Consulting Market FORT MYERS, Fla.–(BUSINESS WIRE)–Foster & Foster Consulting Actuaries, Inc. a premier actuarial and health and welfare plan consulting firm based in Fort Myers, Florida, which represents over 1,000 public pension and health and welfare plans in the United States, announced today … [Read more…]

Virpax Pursues OTC Medical Device Pathway for AnQlar™

BERWYN, Pa.–(BUSINESS WIRE)–#pharma—Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced it will pursue an OTC Intranasal Medical Device Consumer regulatory pathway for AnQlar™, the Company’s product candidate being developed as a … [Read more…]

The MolinaCares Accord Commits $400,000 to the University of Washington School of Nursing to Develop Family and Psychiatric Primary Care Curriculum

BOTHELL, Wash.–(BUSINESS WIRE)–The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Washington (“Molina”), recently committed $400,000 to the University of Washington School of Nursing to help expand the behavioral health workforce in the state through the development and implementation of a blended family and psychiatric primary care curriculum for nurse practitioners. “MolinaCares is dedicated … [Read more…]

Propanc Biopharma’s CEO Comments on the 39 Granted Patents and 26 Patent Applications Under Examination in Key Global Jurisdictions

Current Patents and Planned Future Patent Applications Covers the Company’s Lead Product Candidate, PRP, and Backup Clinical Compounds MELBOURNE, Australia–(BUSINESS WIRE)–Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that CEO and Co-Founder, Mr. James Nathanielsz, BAS, MEI, … [Read more…]

Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema

— Results Continue to Support that STAR-0215 is a Potent, Selective, and Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein — — STAR-0215 Demonstrates Rapid and Sustained Inhibition of Plasma Kallikrein After Subcutaneous Administration in Monkeys — BOSTON–(BUSINESS WIRE)–Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for hereditary angioedema and focused on life-changing therapies for … [Read more…]

BELLUS Health to Participate in the William Blair Biotech Focus Conference

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will be participating in a fireside chat at the William Blair … [Read more…]

Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement

Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros’ Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023 Syros to Host Conference Call at 8:30 AM ET Today CAMBRIDGE, … [Read more…]

Ra Medical Systems Receives FDA 510(k) Clearance for the DABRA 2.0 Catheter

Board of Directors continues its review of strategic alternatives to determine the Company’s optimal path forward CARLSBAD, Calif.–(BUSINESS WIRE)–$RMED #Atherectomy–Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”), a medical device company focusing on developing its excimer laser system to treat vascular diseases, announces receipt of U.S. Food and Drug Administration 510(k) … [Read more…]

KalVista Pharmaceuticals Presents New Data for Sebetralstat and its Oral Factor XIIa Inhibitor Program

– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system – CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease … [Read more…]